Free Trial

Transcat (TRNS) Competitors

Transcat logo
$91.63 +1.24 (+1.37%)
Closing price 04:00 PM Eastern
Extended Trading
$91.78 +0.15 (+0.16%)
As of 04:04 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

TRNS vs. TXG, ALNT, LAB, EYPT, SENS, CTKB, QSI, AEHR, QTRX, and MASS

Should you be buying Transcat stock or one of its competitors? The main competitors of Transcat include 10x Genomics (TXG), Allient (ALNT), Standard BioTools (LAB), EyePoint Pharmaceuticals (EYPT), Senseonics (SENS), Cytek Biosciences (CTKB), Quantum-Si (QSI), Aehr Test Systems (AEHR), Quanterix (QTRX), and 908 Devices (MASS). These companies are all part of the "measuring and control equipment" industry.

Transcat vs.

10x Genomics (NASDAQ:TXG) and Transcat (NASDAQ:TRNS) are both small-cap medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their dividends, media sentiment, valuation, institutional ownership, analyst recommendations, community ranking, profitability, risk and earnings.

Transcat received 147 more outperform votes than 10x Genomics when rated by MarketBeat users. Likewise, 66.04% of users gave Transcat an outperform vote while only 50.39% of users gave 10x Genomics an outperform vote.

CompanyUnderperformOutperform
10x GenomicsOutperform Votes
65
50.39%
Underperform Votes
64
49.61%
TranscatOutperform Votes
212
66.04%
Underperform Votes
109
33.96%

10x Genomics has a beta of 1.94, indicating that its stock price is 94% more volatile than the S&P 500. Comparatively, Transcat has a beta of 0.69, indicating that its stock price is 31% less volatile than the S&P 500.

10x Genomics presently has a consensus price target of $15.81, suggesting a potential upside of 92.07%. Transcat has a consensus price target of $114.00, suggesting a potential upside of 27.62%. Given 10x Genomics' higher probable upside, research analysts clearly believe 10x Genomics is more favorable than Transcat.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
10x Genomics
1 Sell rating(s)
8 Hold rating(s)
7 Buy rating(s)
0 Strong Buy rating(s)
2.38
Transcat
0 Sell rating(s)
2 Hold rating(s)
2 Buy rating(s)
0 Strong Buy rating(s)
2.50

In the previous week, Transcat had 2 more articles in the media than 10x Genomics. MarketBeat recorded 12 mentions for Transcat and 10 mentions for 10x Genomics. 10x Genomics' average media sentiment score of 0.90 beat Transcat's score of 0.36 indicating that 10x Genomics is being referred to more favorably in the media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
10x Genomics
5 Very Positive mention(s)
1 Positive mention(s)
1 Neutral mention(s)
2 Negative mention(s)
0 Very Negative mention(s)
Positive
Transcat
2 Very Positive mention(s)
1 Positive mention(s)
5 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral

Transcat has lower revenue, but higher earnings than 10x Genomics. 10x Genomics is trading at a lower price-to-earnings ratio than Transcat, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
10x Genomics$624.66M1.61-$182.63M-$1.30-6.33
Transcat$278.42M2.99$13.65M$1.5657.26

84.7% of 10x Genomics shares are owned by institutional investors. Comparatively, 98.3% of Transcat shares are owned by institutional investors. 9.4% of 10x Genomics shares are owned by insiders. Comparatively, 2.3% of Transcat shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

Transcat has a net margin of 6.22% compared to 10x Genomics' net margin of -29.90%. Transcat's return on equity of 7.23% beat 10x Genomics' return on equity.

Company Net Margins Return on Equity Return on Assets
10x Genomics-29.90% -25.40% -19.69%
Transcat 6.22%7.23%5.67%

Summary

Transcat beats 10x Genomics on 12 of the 18 factors compared between the two stocks.

Get Transcat News Delivered to You Automatically

Sign up to receive the latest news and ratings for TRNS and its competitors with MarketBeat's FREE daily newsletter.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

TRNS vs. The Competition

MetricTranscatInstruments to measure electricity IndustryComputer SectorNASDAQ Exchange
Market Cap$832.55M$4.14B$25.10B$8.39B
Dividend YieldN/A0.46%2.89%4.10%
P/E Ratio48.3422.1144.5919.71
Price / Sales2.992.372,073.75117.54
Price / Cash27.1417.8734.7834.62
Price / Book2.963.246.644.50
Net Income$13.65M$135.28M$739.99M$248.18M
7 Day Performance10.43%-1.10%-0.94%0.23%
1 Month Performance6.05%12.05%12.57%12.39%
1 Year Performance-37.17%-8.84%52,628.85%7.07%

Transcat Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
TRNS
Transcat
1.2202 of 5 stars
$91.63
+1.4%
$114.00
+24.4%
-36.3%$852.98M$278.42M49.53920News Coverage
Earnings Report
Analyst Upgrade
Analyst Revision
TXG
10x Genomics
4.401 of 5 stars
$9.49
+8.2%
$17.81
+87.6%
-65.3%$1.16B$624.66M-6.241,240Analyst Forecast
ALNT
Allient
2.6271 of 5 stars
$29.85
+3.8%
$31.00
+3.9%
+6.1%$505.33M$516.06M33.921,950Gap Up
LAB
Standard BioTools
2.3385 of 5 stars
$1.16
+8.4%
$2.50
+115.5%
-59.7%$440.59M$169.69M-1.63620Positive News
EYPT
EyePoint Pharmaceuticals
2.4493 of 5 stars
$5.85
+0.7%
$25.29
+332.2%
-49.4%$402.54M$43.27M-2.93120Analyst Revision
Gap Up
SENS
Senseonics
1.887 of 5 stars
$0.60
-4.0%
$2.00
+233.3%
+6.4%$392.53M$22.47M-4.6290Gap Up
CTKB
Cytek Biosciences
2.0451 of 5 stars
$3.02
+3.4%
$5.25
+73.8%
-58.8%$385.35M$197.05M-37.75500News Coverage
Gap Up
QSI
Quantum-Si
2.6192 of 5 stars
$1.51
+19.8%
$3.48
+130.1%
-14.7%$276.54M$3.06M-2.36150News Coverage
Earnings Report
Analyst Forecast
Analyst Revision
Gap Up
AEHR
Aehr Test Systems
3.8929 of 5 stars
$9.11
+7.8%
$25.00
+174.4%
-26.3%$271.21M$61.48M12.1590Positive News
QTRX
Quanterix
1.8292 of 5 stars
$5.73
+8.5%
$16.20
+182.7%
-71.3%$222.26M$135.44M-5.41460Positive News
Analyst Downgrade
Gap Up
MASS
908 Devices
2.8061 of 5 stars
$5.73
+2.0%
$5.33
-6.9%
-28.2%$204.79M$59.63M-3.2460Positive News
Analyst Revision

Related Companies and Tools


This page (NASDAQ:TRNS) was last updated on 5/22/2025 by MarketBeat.com Staff
From Our Partners